Featured Videos

The talks, coffee hours, and networking sessions have all wrapped up from last week’s American Society for Human Genetics (ASHG) meeting. After a few whirlwind days in DC, the GEN team is back at home. Here, Julianna LeMieux, PhD, Deputy Editor in Chief at GEN and Kevin Davies, PhDGEN’s Editor at Large, are joined by Uduak Thomas, Senior Editor at GEN, to recap their biggest takeaways from the meeting.

Thanks DC: GEN Editors’ Final Report from ASHG

The American Society for Human Genetics (ASHG) meeting is off and running! The GEN team is there, on the ground in Washington, DC, reporting on all the latest news. Here, Julianna LeMieux, PhD, Deputy Editor in Chief at GEN and Kevin Davies, PhD, GEN’s Editor at Large take a minute to share their biggest takeaways from the first day at the meeting.

Genetics in DC: A Report from ASHG

November 2023 cover

The Alzheimer’s-afflicted brain is like a garden that has become choked with weeds (amyloid plaques), overrun by destructive pests (abnormal tau), and worn down by severe weather (inflammation). Fortunately, as this month’s cover story explains, each of these threats is being targeted by antibody-based drugs. Indeed, drug developers are looking into combination therapies. And to ensure that therapies are deployed earlier, and to greater effect, investigators are working on blood-based biomarkers. In this issue of GEN, the idea of taming out-of-control processes, and thereby restoring health, isn’t limited to antibody-based Alzheimer’s drugs. It is reflected in feature articles on phage therapies, RNA-based vaccines and drugs, and RNA editing platforms. In addition, this issue of GEN invites readers to look at 3D cell cultures as gardens that can represent the complex ecologies that exist in human tissues. Specifically, organoids are presented as suitable testing grounds for drug developers. Finally, we report on sample prep kits that facilitate the cultivation of lush DNA libraries.